Skip to main content

Actinium Pharmaceuticals Inc (ATNM) Targets Breakthrough in Cancer Therapy: Proprietary Production of Vital Isotope Sparks Industry Buzz and Share Surge

In the dynamic world of biotechnology, innovation is king and the race for progress never slows. Astounding strides are made by companies that not only ride the wave of technological advancement but also create the ripples that drive it forward.

A few names stand out for their striking performance and promising outlook. Leading the pack, Corbus Pharmaceuticals Holdings, Inc. (CRBP) has shown an extraordinary year-to-date return of +564.16%, with a current price of $40.12 and a bullish 1-year target estimate of $55.00. Following closely is Vincerx Pharma, Inc. (VINC), with a notable +463.56% return, its share price at $6.65 and an optimistic future target of $9.00. Janux Therapeutics, Inc. (JANX) also posts strong gains, with a +273.34% return, trading at $40.06 against a target of $44.00. Not to be overshadowed, Viking Therapeutics, Inc. (VKTX), with a +265.30% return, is currently priced at $67.98 and eyes a goal of $106.60. Lastly, Longboard Pharmaceuticals, Inc. (LBPH) rounds out the list with a +244.11% return, its stock value at $20.75, striving towards a target of $41.88. These companies not only represent robust growth in their current standings but also exemplify the innovative momentum driving the biotech industry forward.

One company that is potentially looking solid to make the list of Top Performing Companies In The Biotechnology Industry is Actinium Pharmaceuticals Inc. (NYSE: ATNM). Actinium Pharmaceuticals Inc. (ATNM) is up more than 20 percent in the last two trading sessions. Actinium Pharmaceuticals Inc. (ATNM), at the time of writing this article, was trading at $8.50. ATNM’s stock price surged after Maxim raised the firm’s price target on Actinium Pharmaceuticals (ATNM) to $30 from $20 and keept a Buy rating on the shares following another Ac-225 acquisition with AstraZeneca (AZN) to acquire Fusion Pharma (FUSN). 

The firm notes that the acquisition comes amidst building momentum in the radiopharma space, in particular among alpha emitters, including the December acquisition of RayzeBio (RYZB) by Bristol Meyers (BMY) for $4.1B for its Ac-225 pipeline. Maxim also highlights Lilly (LLY) acquiring POINT Biopharma in October 2023 for $1.4B, which was centered around its pipeline of targeted beta – Lu-177 – and alpha – Ac-225 – emitting radio-pharmaceuticals. The Ac-225 focused M&A activity, which given the small number of companies in the space, places a potential “scarcity value” on Actinium, the firm argues.

Recently, Actinium Pharmaceuticals (NYSEAMERICAN: ATNM), Inc, specializing in Antibody-Radio Conjugates (ARCs) and targeted radiotherapies, announced the initiation of a new strategic initiative to produce the medical isotope Actinium-225 (Ac-225) using its proprietary cyclotron-based technology. Ac-225 is a valuable alpha-particle emitter used in targeted radiotherapies for cancer treatment, known for its ability to effectively kill cancer cells by causing double-strand DNA breaks, a damage mechanism that cells are unable to repair or resist. Actinium's production method for Ac-225, which is supported by an extensive intellectual property portfolio, promises to deliver a highly pure product that matches the gold-standard Thorium-229 generator method but with the potential benefits of lower costs and higher yields when produced at a commercial scale.

Sandesh Seth, Actinium's Chairman and CEO, said, "Significant efforts and investments have been made by Actinium in developing our proprietary method and related intellectual property and know-how. With our Ac-225 based Actimab-A program advancing to late-stage trials under our CRADA with the NCI and the rapidly increasing number of Ac-225 based programs in development, the time is now to fully realize the potential of our production method. We are excited to launch this initiative and are committed to making further strategic investments to bring our method to commercial scale while engaging with potential collaborators and partners globally to maximize the value of our patents and capabilities, as well as to ensure supply for our increasing Ac-225 based product development efforts and address the growing clinical demand."

In summary, Actinium Pharmaceuticals Inc. (ATNM) emerges as a burgeoning contender, its stock climbing by more than 20% in recent sessions. Trading at $8.50, ATNM's valuation has soared following bullish analyst revisions and strategic acquisitions in the radiopharma space that underscore the company's potential and the industry's growing interest in targeted radiotherapies. The pioneering initiative by Actinium to manufacture the medical isotope Actinium-225 with proprietary technology not only fortifies its standing but also hints at a broader impact, possibly altering the therapeutic landscape and contributing to a reshaped market outlook. With such developments at hand, ATNM is a name that resonates with possibility and warrants close attention in the ever-evolving narrative of biotech excellence. As always, conduct your own due diligence and follow traders vigilance. 

Disclaimer: This blog post is for informational purposes only and does not constitute financial advice or an endorsement of ATNM or its strategies. FOR EDUCATIONAL AND INFORMATION PURPOSES ONLY; NOT INVESTMENT ADVICE. Please ensure to fully read and comprehend our disclaimer found at has been compensated a total of three thousand dollars by a 3rd party Bullzeyemedia LLC for content distribution services on ATNM from March 20th to March 25th, 2024. We own zero shares of ATNM. is neither an investment advisor nor a registered broker. No current owner, employee, or independent contractor of is registered as a securities broker-dealer, broker, investment advisor, or IA representative with the U.S. Securities and Exchange Commission, any state securities regulatory authority, or any self-regulatory organization. This article may contain forward-looking statements as defined under Section 27A of the Securities Act of 1933 and 21E of the Exchange Act of 1934. These statements, often incorporating terms like “believes,” “anticipates,” “estimates,” “expects,” “projects,” “intends,” or similar expressions about future performance or conduct, are based on present expectations, estimates, and projections, and are not historical facts. They carry various risks and uncertainties that may result in significant deviation from the anticipated results or events. Past performance does not guarantee future does not commit to updating forward-looking statements based on new information or future events. Readers are encouraged to review all public SEC filings made by the profiled companies at It is always important to conduct thorough due diligence and exercise caution in is not managed by a licensed broker, a dealer, or a registered investment adviser. The content here is purely informational and should not be taken as investment advice. The Private Securities Litigation Reform Act of 1995 provides investors a safe harbor regarding forward-looking statements. Any statement that projects, foresees, expects, anticipates, estimates, believes, or understands certain actions to possibly occur are not historical facts and may be forward-looking statements. These statements are based on expectations, estimates, and projections that could cause actual results to differ greatly from those anticipated. Investing in micro-cap and growth securities is speculative and entails a high degree of risk, potentially leading to a total or substantial loss of investment. Please note that no content published here constitutes a recommendation to buy or sell a security. It is solely informational, and you should not construe it as legal, tax, investment, financial, or other advice. No content in this article constitutes an offer or solicitation by or any third-party service provider to buy or sell securities or other financial instruments. The content in this article does not address the circumstances of any specific individual or entity and does not constitute professional and/or financial advice. is not a fiduciary by virtue of any person’s use of or access to this content.


Media Contact
Company Name: Investor Brand Media
Contact Person: Ash K
Phone: (954) 593-5597
Country: United States

Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.